Neurogene Reports First Patient Dosed In High-Dose Cohort Of NGN-401 Gene Therapy Clinical Trial For Rett Syndrome
Portfolio Pulse from Benzinga Newsdesk
Neurogene Inc. (NASDAQ:NGNE) announced the first patient in Cohort 2 received high-dose NGN-401 gene therapy in the Phase 1/2 trial for Rett syndrome. The high-dose has been well-tolerated, and the low-dose continues to show a favorable safety profile with no new treatment-related adverse events.
June 18, 2024 | 1:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Neurogene Inc. reported positive interim safety data for its NGN-401 gene therapy in a Phase 1/2 trial for Rett syndrome. The high-dose has been well-tolerated, and the low-dose continues to show a favorable safety profile with no new treatment-related adverse events.
The positive interim safety data for NGN-401 gene therapy in the Phase 1/2 trial for Rett syndrome is likely to boost investor confidence in Neurogene Inc. The well-tolerated high-dose and favorable safety profile of the low-dose suggest potential efficacy and safety, which are critical for the success of clinical trials and future regulatory approvals.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100